Zedira licenses ZED-101 for celiac disease therapy to Dr. Falk Pharma in Europe
Advertisement
Zedira GmbH today announced that it has licensed exclusive rights to develop and market ZED-101 in Europe to Dr. Falk Pharma GmbH, Germany. ZED-101 is a new chemical entity blocking specifically tissue transglutaminase. Tissue transglutaminase is the key player in pathogenesis of celiac disease.
Under the terms of the agreement, Dr. Falk Pharma GmbH takes over preclinical and clinical development as well as marketing of the drug.
Zedira receives an upfront payment and may receive further milestone payments as well as royalties.